No Need To Fight: Teva Retains Provigil Generic Exclusivity Even Without “Adversarial” Relationship
This article was originally published in The Pink Sheet Daily
U.S. Judge Ellen Segal Huvelle denies Mylan’s request to block the agency’s award of modafinil 180-day marketing rights to Teva. Mylan’s argument that the existence of an adversarial relationship between an ANDA first-filer and NDA holder is necessary for an award of generic marketing exclusivity is “fatally flawed,” the judge says, although she expresses sympathy for the plaintiff’s Hatch-Waxman policy arguments.
You may also be interested in...
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.
Provigil Generic Exclusivity Decision “Eviscerates” Hatch-Waxman, FTC Says
In a strongly worded amicus brief filed in Mylan’s lawsuit against FDA, the Federal Trade Commission says it would have required different remedies in clearing Teva’s acquisition of Cephalon last year had it known the Israel-based firm would receive sole 180-day marketing exclusivity for modafinil.